Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05886920 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
A Phase 1 study of Advanced Solid Tumors With MAPK Pathway Mutations, sponsored by D3 Bio (Wuxi) Co..
- Active
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
- 10
- Study locations
NCT05886920: Active Phase 1 study of Advanced Solid Tumors With MAPK Pathway Mutations, sponsored by D3 Bio (Wuxi) Co..
NCT05886920 is a Phase 1 study of Advanced Solid Tumors With MAPK Pathway Mutations that is active but no longer recruiting, run by D3 Bio (Wuxi) Co.. The registered enrollment target is 67 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% higher). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05886920, a Phase 1 study of Advanced Solid Tumors With MAPK Pathway Mutations, is active but no longer recruiting, sponsored by D3 Bio (Wuxi) Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
- 10
- Study locations
Study Summary
This first-in-human (FIH) study aims to assess the safety, tolerability, pharmacokinetics, and recommended phase 2 dose (RP2D) of D3S-002 given orally daily for 21-day cycles in adult subjects with advanced solid tumors with mitogen-activated protein kinase (MAPK) pathway mutations.
Conditions Studied
Interventions
- DRUG D3S-001
- DRUG D3S-002
Study Locations (10)
Michigan
- D3 Bio Investigative Site - Detroit
New York
- D3 Bio Investigative Site - New York
New South Wales
- D3 Bio Investigative Site - Blacktown
South Australia
- D3 Bio Investigative Site - Bedford Park
Western Australia
- D3 Bio Investigative Site - Nedlands
Beijing Municipality
- D3 Bio Investigative Site - Beijing
Guangdong
- D3 Bio Investigative Site - Guangzhou
Heilong Jiang
- D3 Bio Investigative Site - Harbin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2023-07-10 |
| Est. Completion | 2028-04 |
| Phase | Phase 1 |
What the registry record for NCT05886920 still lists
NCT05886920 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% higher).
The record links to 1 condition, with Advanced Solid Tumors With MAPK Pathway Mutations appearing as the primary indexed condition, and to 2 interventions - of which D3S-001 is the first listed.
NCT05886920 lists 10 locations in 10 states (Michigan, New York, New South Wales).
Frequently Asked Questions
What is clinical trial NCT05886920 about?
NCT05886920 is a clinical study titled "A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations". This first-in-human (FIH) study aims to assess the safety, tolerability, pharmacokinetics, and recommended phase 2 dose (RP2D) of D3S-002 given orally daily for 21-day cycles in adult subjects with advanced solid tumors with mitogen-activated protein kinase (MAPK) pathway mutations.
What is the current status of trial NCT05886920?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2023-07-10. Estimated completion is 2028-04.
What conditions does trial NCT05886920 study?
This clinical trial studies the following conditions: Advanced Solid Tumors With MAPK Pathway Mutations.
What interventions are being tested in trial NCT05886920?
The interventions under investigation include: D3S-001 (DRUG), D3S-002 (DRUG).
Who is sponsoring clinical trial NCT05886920?
This trial is sponsored by D3 Bio (Wuxi) Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05886920 being conducted?
This trial has 10 study locations across Michigan, New York, New South Wales, South Australia, Western Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05886920's enrollment target sits among peer trials
67 782nd of 2000 higher than 1,215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI